title: First experience using peptide receptor radionuclide therapy in a patient with urothelial carcinoma.
abstract: A 78-year-old man with urothelial carcinoma metastasis after surgical resection of the right kidney, part of the ureter, and urinary bladder in May 2003 and 3 cycles of chemotherapy with cisplatin-gemcitabine was referred for peptide receptor radionuclide therapy (PRRT). Somatostatin-receptor profile was assessed by 68Ga-labeled lanreotide PET, and PRRT was performed using 3738 MBq (101 mCi) of 90Y-DOTA-lanreotide. Because of adequate PRRT response confirmed with MRI and 18F-FDG PET, surgical resection of the solitary cervical metastasis was feasible. Treatment was well tolerated, and the patient remains in complete remission from his urothelial carcinoma.
authors.affiliation: From the *Department of Nuclear Medicine and †Department of Surgery, Innsbruck Medical University, Innsbruck, Austria.
authors.forename: Daniel
authors.initials: D
authors.lastname: Putzer
authors.forename: Michael
authors.initials: M
authors.lastname: Gabriel
authors.forename: Rupert
authors.initials: R
authors.lastname: Prommegger
authors.forename: Dorota
authors.initials: D
authors.lastname: Kendler
authors.forename: Irene Johanna
authors.initials: IJ
authors.lastname: Virgolini
mesh_terms: D000368:Aged; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D018000:Receptors, Peptide / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*
chemical_list: D010456:Peptides, Cyclic; D018000:Receptors, Peptide; C060347:lanreotide; D013004:Somatostatin